Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 96.13%
March 31, 2026 95.76%
December 31, 2025 94.14%
September 30, 2025 96.67%
June 30, 2025 98.45%
March 31, 2025 94.79%
December 31, 2024 95.92%
September 30, 2024 95.09%
June 30, 2024 95.67%
March 31, 2024 93.47%
December 31, 2023 97.35%
September 30, 2023 94.60%
June 30, 2023 95.63%
March 31, 2023 94.68%
December 31, 2022 92.74%
September 30, 2022 95.86%
June 30, 2022 92.65%
March 31, 2022 93.61%
December 31, 2021 98.41%
September 30, 2021 94.15%
June 30, 2021 93.66%
March 31, 2021 93.34%
December 31, 2020 97.39%
September 30, 2020 95.29%
June 30, 2020 95.16%
Date Value
March 31, 2020 95.01%
December 31, 2019 98.97%
September 30, 2019 97.23%
June 30, 2019 96.93%
March 31, 2019 98.46%
December 31, 2018 97.76%
September 30, 2018 0.00%
June 30, 2018 0.00%
March 31, 2018 0.00%
December 31, 2017
September 30, 2017 0.00%
June 30, 2017 0.00%
March 31, 2017 0.00%
December 31, 2016 0.00%
September 30, 2016 0.00%
June 30, 2016 0.00%
March 31, 2016 0.00%
December 31, 2015 0.00%
September 30, 2015 0.00%
June 30, 2015 0.00%
March 31, 2015 0.00%
December 31, 2014 0.00%
September 30, 2014 0.00%
June 30, 2014 0.00%
March 31, 2014 0.00%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 76.88%
Biogen, Inc. 61.37%
BridgeBio Pharma, Inc. 93.68%
Vertex Pharmaceuticals, Inc. 85.37%
Pfizer Inc. 62.94%

Gross Profit Margin (Quarterly) Related Metrics